Across TCGA pan-cancer cohorts, TMEM17 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMEM17 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMEM17 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM17 expression acts as an unfavorable survival marker.

CCRCC, LSCC, and PDAC are the cancer types where TMEM17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.341	1.000	.008	44	view →
LSCC	DFS	Tertile	III,IV	0.502	0.918	.019	7	view →
PDAC	DFS	Median	All	0.224	0.730	.042	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TMEM17 tumor-vs-normal RNA expression · all TMEM17 data types